GILEAD SCIENCES INC. - US3755581036 (Stock)
Berlin
| Price | Diff.% | Date & Time | Bid volume | Bid | Ask | Ask volume |
|---|---|---|---|---|---|---|
98,50 EUR
|
-0,4044% | 31.07.2025 08:08 | 150,00 | 99,26 | 100,04 | 150,00 |
| Contact | |
|---|---|
|
Gilead Sciences Inc. 333 Lakeside Drive 94404, Foster City, US |
| Phone | +1-650-574-3000 |
| Fax | +1-650-522-5853 |
| Internet | http://www.gilead.com |
| IR Contact/PR Contact | -/- |
| Symbol | GILD |
| End of financial year | 31.12.2025 |
| Issued capital | 124.913.228.045,00 EUR |
| Shareholders | |
|---|---|
| Freefloat | 59,86% |
| The Vanguard Group, Inc. | 8,94% |
| BlackRock Fund Advisors | 5,67% |
| SSgA Funds Management, Inc. | 4,78% |
| Capital Research & Management Co. (Global Investors) | 4,38% |
| Capital Research & Management Co. (World Investors) | 4,30% |
| Fidelity Management & Research Co. LLC | 3,51% |
| Dodge & Cox | 2,62% |
| Geode Capital Management LLC | 2,29% |
| Wellington Management Co. LLP | 2,10% |
| Norges Bank Investment Management | 1,55% |
| Board | |
|---|---|
| Javier Rodriguez | Member of Board of Directors |
| Harish M. Manwani | Member of Board of Directors |
| Anthony Welters | Member of Board of Directors |
| Dr. Ted Love | Member of Board of Directors |
| Dr. Sandra Horning | Member of Board of Directors |
| Dr. Jeffrey Bluestone | Member of Board of Directors |
| Dr. Jacqueline Barton | Member of Board of Directors |
| Kelly Kramer | Member of Board of Directors |
| Daniel O'Day | Chairman of Managing Board |
| MD. PhD Dietmar Berger | Member of Executive Committee |
| Jyoti Mehra | Member of Executive Committee |
| Johanna Mercier | Member of Executive Committee |
| Flavius Martin | Member of Executive Committee |
| Deborah H. Telman | Member of Executive Committee |
| Cindy Perettie | Member of Executive Committee |
| Andrew Dickinson | Member of Executive Committee |
| Stacey Ma | Member of Executive Committee |
| Activity Description |
|---|
|
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. |
© 2000 - 2025 UniCredit Bank Austria AG. Please read our terms and conditions
Implemented and powered by FactSet
Fond data is provided from Mountain-View Data Gmbh
Austria-HomePage Version 2.0.54
